759 related articles for article (PubMed ID: 24524660)
1. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
[TBL] [Abstract][Full Text] [Related]
2. A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A; Mayo NE
Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
[TBL] [Abstract][Full Text] [Related]
3. An exploratory study to test the impact on three "bolt-on" items to the EQ-5D.
Yang Y; Rowen D; Brazier J; Tsuchiya A; Young T; Longworth L
Value Health; 2015 Jan; 18(1):52-60. PubMed ID: 25595234
[TBL] [Abstract][Full Text] [Related]
4. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).
Brazier JE; Rowen D; Mavranezouli I; Tsuchiya A; Young T; Yang Y; Barkham M; Ibbotson R
Health Technol Assess; 2012 Jul; 16(32):1-114. PubMed ID: 22832015
[TBL] [Abstract][Full Text] [Related]
5. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
6. Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.
Young TA; Mukuria C; Rowen D; Brazier JE; Longworth L
Med Decis Making; 2015 Oct; 35(7):912-26. PubMed ID: 25997920
[TBL] [Abstract][Full Text] [Related]
7. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
8. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
9. Testing the Psychometric Properties of 9 Bolt-Ons for the EQ-5D-5L in a General Population Sample.
Rencz F; Janssen MF
Value Health; 2024 Apr; ():. PubMed ID: 38599517
[TBL] [Abstract][Full Text] [Related]
10. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
[TBL] [Abstract][Full Text] [Related]
11. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
12. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures.
Brazier J; Connell J; Papaioannou D; Mukuria C; Mulhern B; Peasgood T; Jones ML; Paisley S; O'Cathain A; Barkham M; Knapp M; Byford S; Gilbody S; Parry G
Health Technol Assess; 2014 May; 18(34):vii-viii, xiii-xxv, 1-188. PubMed ID: 24857402
[TBL] [Abstract][Full Text] [Related]
13. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
14. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
[TBL] [Abstract][Full Text] [Related]
15. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
16. Selecting Bolt-on Dimensions for the EQ-5D: Testing the Impact of Hearing, Sleep, Cognition, Energy, and Relationships on Preferences Using Pairwise Choices.
Finch AP; Brazier J; Mukuria C
Med Decis Making; 2021 Jan; 41(1):89-99. PubMed ID: 33256502
[TBL] [Abstract][Full Text] [Related]
17. Selecting Bolt-On Dimensions for the EQ-5D: Examining Their Contribution to Health-Related Quality of Life.
Finch AP; Brazier JE; Mukuria C
Value Health; 2019 Jan; 22(1):50-61. PubMed ID: 30661634
[TBL] [Abstract][Full Text] [Related]
18. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
